Novel Cancer Drug in China Stabilizes US Patient
What happened
A U.S. patient with advanced lung cancer has been stabilized using a novel immunotherapy treatment called ivonescimab, currently available only in China. The case at Shanghai's Jiahui International Cancer Center highlights the growing role of international collaboration in advanced medical care.
Why it matters
Ivonescimab, developed by Chinese biopharmaceutical company Akeso, is a novel bispecific antibody. It works by simultaneously targeting two pathways that fuel cancer: it blocks the PD-1 protein to activate an immune response against the tumor and inhibits VEGF to cut off the tumor's blood supply. The American patient, a man in his 70s also battling Parkinson's disease, had exhausted all standard
Key numbers
- It works by simultaneously targeting two pathways that fuel cancer: it blocks the PD-1 protein to activate an immune response against the tumor and inhibits VEGF to cut off the tumor's blood supply.
- The American patient, a man in his 70s also battling Parkinson's disease, had exhausted all standard
Quick answers
What happened in Novel Cancer Drug in China Stabilizes US Patient?
A U.S. patient with advanced lung cancer has been stabilized using a novel immunotherapy treatment called ivonescimab, currently available only in China. The case at Shanghai's Jiahui International Cancer Center highlights the growing role of international collaboration in advanced medical care.
Why does Novel Cancer Drug in China Stabilizes US Patient matter?
Ivonescimab, developed by Chinese biopharmaceutical company Akeso, is a novel bispecific antibody. It works by simultaneously targeting two pathways that fuel cancer: it blocks the PD-1 protein to activate an immune response against the tumor and inhibits VEGF to cut off the tumor's blood supply. The American patient, a man in his 70s also battling Parkinson's disease, had exhausted all standard
